GlassScriptPhysician profile
Jonathan Kristan
NPI 1629450101
$2,870.92
in general payments reported to CMS, 2019-2025
24 companies · $531 in 2025
The $531 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $120 · 2020: $205 · 2021: $359 · 2022: $567 · 2023: $546 · 2024: $541 · 2025: $531.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,618.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,618.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $448.45 | 2022-2025 | Catalys System, Tecnis Iol, Tecnis Iol |
| Allergan, INC. | $432.45 | 2019-2021 | |
| Alcon Vision LLC | $236.44 | 2022-2025 | Eysuvis, Rocklatan, Simbrinza |
| Sun Pharmaceutical Industries INC. | $222.83 | 2019-2025 | Cequa |
| Bausch & Lomb Americas INC. | $219.26 | 2022-2025 | Xiidra, Miebo, Envista Mx60 Iol |
| Glaukos Corporation | $169.86 | 2022-2025 | Idosetr |
| Tarsus Pharmaceuticals, INC. | $158.30 | 2024-2025 | Xdemvy |
| Abbvie INC. | $132.96 | 2022-2025 | |
| Oyster Point Pharma, INC. | $127.18 | 2022-2025 | Tyrvaya |
| Alexion Pharmaceuticals, INC. | $90.52 | 2022-2023 | Ultomiris |
| Ocular Therapeutix, INC. | $85.77 | 2023-2024 | Dextenza |
| Rxsight INC | $76.67 | 2023-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Harrow Eye, LLC | $68.22 | 2024-2025 | Vevye |
| Sight Sciences, INC. | $65.74 | 2022-2023 | Omni Surgical System |
| Regeneron Healthcare Solutions, INC. | $59.15 | 2021-2024 | Eylea |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $55.02 | 2020-2022 | |
| Amgen INC. | $52.51 | 2024-2025 | Tepezza |
| Kala Pharmaceuticals, INC. | $41.96 | 2020-2021 | |
| Eyevance Pharmaceuticals LLC | $38.89 | 2021-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $28.86 | 2020-2021 | |
| Omeros Corporation | $16.99 | 2021 | |
| Mallinckrodt Hospital Products INC. | $16.75 | 2021 | |
| Thea Pharma INC. | $14.22 | 2025 | Iyuzeh |
| Merz Pharmaceuticals, LLC | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Kristan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.